Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
"Acadia has misrepresented Daybue's safety profile, and in turn, patent retention rates," Culper Research alleged in its report. Culper Research discloses short position in Acadia Pharma Skip to ...
After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease med Nuplazid. Acadia plans to ...
Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. [ 5 ] [ 6 ] [ 7 ] Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia -related psychosis, [ 8 ] major depressive disorder , [ 9 ] schizophrenia ...
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings ...
In March 2024, Acadia Pharmaceuticals announced its decision to stop any further clinical trials of pimavanserin after the drug did not improve negative symptoms of schizophrenia better than placebo. [ 28 ]
ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a K i of 5 nM, and no significant affinity for any other receptors tested.